Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.52 |
| ▸ | ACACA | Q13085 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27291368 | 0.88 | ACACB (0.39) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL31707540 | 0.88 | ACACB (0.38) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL23588102 | 0.88 | SPHK1 (0.48) | TP53MAPTFFAR1S1PR1NPC1 | |
| SCHEMBL23588271 | 0.87 | SPHK1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL23578433 | 0.86 | ACACB (0.57) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL29973428 | 0.86 | GSTP1 (0.40) | ACACBACACATP53MAPTFFAR1 | |
| SCHEMBL23578220 | 0.86 | GSTP1 (0.40) | ACACBACACATP53MAPTFFAR1 | |
| SCHEMBL25802078 | 0.85 | FFAR1 (0.50) | FFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30880252 | 0.85 | ACACB (0.56) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL25802137 | 0.85 | MAPT (0.50) | MAPTFFAR1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024089421-A1 | TETRAZOLE DERIVATIVES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-05-02 | — | — | WO | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4081511-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2022-11-02 | — | — | EP | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | ACACB 358/4885ACACA 144/4885MITF 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.